$CLOV Cashflow Statement | Understand Stock

$CLOV

$4.63 +$0.07 (1.54%) Close

$CLOV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization expense
Amortization of notes and securities discounts and debt issuance costs
Loss on disposal of property and equipment
Stock-based compensation
Paid-in-kind interest
Change in fair value of warrants and amortization of warrants
Change in derivative liabilities
Accretion, net of amortization
Net realized losses (gains) on available-for-sale securities
Asset impairment charges
Change in accrued interest earned
Net realized gains on investment securities
Gain on debt extinguishment on note payable
Loss on investment
Premium deficiency reserve
Impairment of goodwill and other intangible assets
Premium deficiency reserve benefit
Changes in operating assets and liabilities:
Accrued retrospective premiums
Other receivables
Reinsurance recoverable
Surety bonds and deposits
Prepaid expenses
Other assets
Healthcare receivables
Non-Insurance receivable
Operating lease right-of-use assets
Unpaid claims
Accounts payable and accrued expenses
Accrued salaries and benefits
Premium deficiency reserve
Reinsurance premium payable
Deferred revenue
Deferred rent
Other liabilities
Non-Insurance performance year obligation
Direct Contracting payable
Non-Insurance payable
Operating lease liabilities
Net cash (used in) provided by operating activities from continuing operations
Net cash used in operating activities from discontinued operations

Net cash (used in) provided by operating activities
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities
Proceeds from sales of short-term investments and available-for-sale securities
Proceeds from maturities of held-to-maturity securities
Proceeds from maturities of short-term investments and available-for-sale securities
Acquisition of business, net of cash acquired
Purchases of property and equipment
Acquisition of Clover Therapeutics Series A preferred shares
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from issuance of convertible notes
Deferred financing costs
Payment of notes payable principal
Change in restricted cash related to surety bonds, deposits, and escrow accounts
Issuance of common stock, net of early exercise liability
Proceeds from reverse recapitalization, net of transaction costs
Buyback and subsequent cancellation of common shares
Proceeds received for the exercise of public and private warrants
Issuance of common stock under employee stock purchase plan, net of stock issuance costs
Payment for the redemptions of public warrants
Cash paid for shares withheld related to stock-based compensation
Repurchases of common stock
Acquisition of noncontrolling interest
Net cash used in financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash paid during the period for interest
Cash paid during the year for health insurance industry fee
Fair value of warrants issued in connection with notes payable
Settlement of bridge loan in connection with convertible notes
Conversion of preferred stock to common stock
Issuance of common stock related to convertible debt
Capital contribution for extinguishment of debt
Activities from Seek Dissolution
Issuance of common stock related to warrants exercised
Acquisition of public and private warrants
Issuance of common stock related to the exercise of public and private warrants
Right-of-use assets obtained in exchange for lease liabilities
Recognition of equity method investments and preferred stock
Derecognition of non-controlling interest
Conversion of Clover Therapeutics convertible note to preferred stock
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents
Restricted cash

Comments